5-Amino-1MQ (Research Compound — Not a Peptide)

Mechanism of action: Inhibits NNMT enzyme activity; Proposed effects on cellular NAD+/SAM metabolism in adipose tissue (preclinical); Proposed influence on fat cell energy expenditure (preclinical)

Proposed indications: Metabolic health (preclinical); Fat loss (preclinical); Body composition (preclinical)

Commonly reported by peptide clinics†: 50 mg once daily, oral (sometimes up to 100-150 mg/day)

Commonly reported at 50 mg once daily, oral capsule form, consistently across multiple independent research-chemical/wellness sources (sometimes extended to 100-150 mg/day). No human clinical trials exist for 5-Amino-1MQ -- this compound has only been studied in animal/cell models; this figure reflects community convention, not evidence.

†Reported by peptide clinics and compounding pharmacies -- not derived from human clinical trials. Not an individualized recommendation. Actual use should be supervised by a qualified provider.

Typical clinical dosing schedule: No established clinical dosing. Human use has been limited to early-phase, primarily preclinical research.

Administration: Oral capsule or injectable (research settings) — No established clinical dosing

Compare with: AOD-9604MOTS-cTesamorelinSemaglutide

An "emerging / limited evidence" rating means rigorous research hasn't caught up yet -- not that this peptide doesn't work. Many peptides in this category are newer or simply understudied rather than proven ineffective.

Evidence rating: ⭐⭐☆☆☆ — In diet-induced obese mice, 5-amino-1MQ inhibited NNMT and was associated with increased cellular energy expenditure and reduced adiposity/body weight (Neelakantan et al., 2018). This is mouse/preclinical evidence — no demonstrated human weight-loss effect exists.

Common side effects: Human safety profile remains incompletely characterized.

Serious risks: Unknown long-term safety; most available data is preclinical/animal-based (mouse studies).

Legal status: Not a peptide — this is a small-molecule NNMT inhibitor, included here for discoverability since it's often searched alongside peptides. Not FDA-approved for human use. This is a research compound, not a medication — any use should only occur under the direction of a licensed healthcare provider, and its legal availability varies and changes frequently. Verify current status independently before considering use.

Regulatory status: Research compound (small molecule, not a peptide) • Not FDA approved

Contraindications: Not established. Avoid in:; Pregnancy; Active malignancy; Uncontrolled illness outside research settings

Pregnancy & breastfeeding: Avoid.

Neelakantan H, Vance V, Wetzel MD, et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology.